ArticleActa biomaterialia2009
Multilayer mediated forward and patterned siRNA transfection using linear-PEI at extended N/P ratios.
Article in Acta biomaterialia, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 60 citations in OpenAlex.
- Inhibition of calreticulin by protein nanoparticles carrying antisense oligonucleotides reduce gene expression and infection ofNanomedicine (London, England) · 2025Article
- PSMA-targeted theranostic nanoplatform achieves spatiotemporally precise therapy and triggers ferroptosis in prostate cancer treatment.Journal of experimental & clinical cancer research : CR · 2025Article
- Analyzing siRNA Concentration, Complexation and Stability in Cationic Dendriplexes by Stem-Loop Reverse Transcription-qPCR.Pharmaceutics · 2022Article
- An artificial cationic oligosaccharide combined with phosphorothioate linkages strongly improves siRNA stability.Scientific reports · 2020Article
- Transfection of hard-to-transfect primary human macrophages withRNA biology · 2020Article
- Biomaterial substrate modifications that influence cell-material interactions to prime cellular responses to nonviral gene delivery.Experimental biology and medicine (Maywood, N.J.) · 2019Review
- Bioreducible Poly(Amino Ethers) Based mTOR siRNA Delivery for Lung Cancer.Pharmaceutical research · 2018Article
- MicroRNA delivery for regenerative medicine.Advanced drug delivery reviews · 2015Review
- A fabricated siRNA nanoparticle for ultra-long gene silencingAdvanced functional materials · 2013Article
- Surface-mediated nucleic acid delivery by lipoplexes prepared in microwell arrays.Small (Weinheim an der Bergstrasse, Germany) · 2013Article
- Matrix metalloproteinase-inspired suicidal treatments of diabetic ulcers with siRNA-decorated nanofibrous meshes.Gene therapy · 2013Article
- Nanotopography-mediated reverse uptake for siRNA delivery into neural stem cells to enhance neuronal differentiation.Scientific reports · 2013Article
- An influenza virus-inspired polymer system for the timed release of siRNA.Nature communications · 2013Article
- Combining topographical and genetic cues to promote neuronal fate specification in stem cells.Biomacromolecules · 2012Review
- Time controlled release of arabinofuranosylcytosine (Ara-C) from agarose hydrogels using layer-by-layer assembly: an in vitro study.Journal of biomaterials science. Polymer edition · 2012Article
- POLYELECTROLYTE MULTILAYER STAMPING IN AQUEOUS PHASE AND NON-CONTACT MODE.Industrial & engineering chemistry research · 2011Article
- Degradable polyelectrolyte multilayers that promote the release of siRNA.Langmuir : the ACS journal of surfaces and colloids · 2011Article
- Controlled release of anti-inflammatory siRNA from biodegradable polymeric microparticles intended for intra-articular delivery to the temporomandibular joint.Pharmaceutical research · 2011Article
- High-throughput screening of microscale pitted substrate topographies for enhanced nonviral transfection efficiency in primary human fibroblasts.Biomaterials · 2011Article
- Emerging links between surface nanotechnology and endocytosis: impact on nonviral gene delivery.Nano today · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Gene delivery from a substrate depends, in part, on the vector-nucleic acid complex that is bound to the surface and the cell adhesive properties of the surface. Here, we present a method to deliver patterns of small interfering RNA (siRNA) that capitalize on a forward transfection method (transfection by introducing siRNA transfection reagent complexes onto plated cells); herein denoted as multilayer mediated forward transfection (MFT). This method separates the substrate-mediated delivery from the cell adhesive properties of the surface. pH responsive layer-by-layer (LbL) assembled multilayers were used as the delivery platform and microcontact printing technique (microCP) was used to pattern nanoparticles of transfection reagent-siRNA complexes onto degradable multilayers. Efficient MFT depend on optimal formulation of the nanoparticles. 25 kDa linear polyethylenimine (LPEI) was optimized as the siRNA transfection reagent for normal forward transfection (NFT) of the nanoparticles. A broad range of LPEI-siRNA nitrogen/phosphate (N/P) ratios (ranging from 5 to 90) was evaluated for the relative amounts of siRNA incorporated into the nanoparticles, nanoparticle size and NFT efficiencies. All the siRNA was incorporated into the nanoparticles at N/P ratio near 90. Increasing the amount of siRNA incorporated into the nanoparticles, with increasing N/P ratio correlated with a linear blue shift in the ultraviolet/visible (UV/vis) absorbance spectrum of the LPEI-siRNA nanoparticles. NFT efficiency greater than 80% was achieved with minimal cytotoxicity at N/P ratio of 30 and siRNA concentration of 200 nM. Similarly, MFT efficiency 60% was achieved for LPEI-siRNA nanoparticles at N/P ratios greater than 30.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.